The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
KIT Pathway Alterations in Mucosal Melanomas of the Vulva and Other Sites
Abstract
Purpose: A significant proportion of mucosal melanomas contain alterations in KIT. The aim of this study was to characterize the pattern of KIT, NRAS, and BRAF mutations in mucosal melanomas at specific sites and to assess activation of the KIT downstream RAF/MEK/extracellular signal-regulated kinase (ERK) and phosphoinositide 3-kinase (PI3K)/AKT pathways in mucosal melanoma specimens. Experimental Design: Seventy-one primary mucosal melanomas from various sites were studied. Mutation analysis was done by DNA sequencing. Expression of KIT, phosphorylated (p)-ERK, and p-AKT was evaluated by immunohistochemistry. Results: KIT mutations were detected in 35% (8 of 23) of vulvar, 9% (2 of 22) of anorectal, 7% (1 of 14) of nasal cavity, and 20% (1 of 5) of penile melanomas. No KIT mutations were found in 7 vaginal melanomas. The difference in KIT mutation frequency between vulvar and nonvulvar cases was statistically significant (P = 0.014). The overall frequencies of NRAS and BRAF mutations were 10% and 6%, respectively. Notably, vaginal melanomas showed a NRAS mutation rate of 43%. KIT gene amplification (≥4 copies), as assessed by quantitative real-time PCR, was observed in 19% of cases. KIT expression was associated with KIT mutation status (P < 0.001) and was more common in vulvar than nonvulvar tumors (P = 0.016). Expression of p-ERK and p-AKT was observed in 42% and 59% of tumors, respectively, and occurred irrespective of KIT/NRAS/BRAF mutation status. NRAS mutation was associated with worse overall survival in univariate analysis. Conclusions: Results show that KIT mutations are more common in vulvar melanomas than other types of mucosal melanomas and that both the RAF/MEK/ERK and PI3K/AKT pathways are activated in mucosal melanoma specimens. Clin Cancer Res; 17(12); 3933–42. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Melanoma biology and new targeted therapy
Gray-Schopfer, V., Wellbrock, C., & Marais, R. (2007) · Nature · doi:10.1038/nature05661 · Cited by 1,371
Determinants of BRAF Mutations in Primary Melanomas
Maldonado, J. L., Fridlyand, J., Patel, H., Jain, A. N., Busam, K., Kageshita, T., Ono, T., Albertson, D. G., Pinkel, D., & Bastian, B. C. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg123 · Cited by 664 · cited 1×
“5) 6/22 (27) 8/20 (40) 11/20 (55) Nasal cavity 1/14 (7) 2/14 (14) 0/14 (0) 4/14 (28) 7/11 (64) 9/11 (82) Vagina 0/7 (0) 3/7 (43) 0/7 (0) 1/7 (14) 4/7 (57) 4/7 (57) Penis 1/5 (20) 1/5 (20) 1/5 (20) 1/5 (20) 1/5 (20) 1/5 (20) Total 12/71 (17) 7/71 (10) 4/71 (6) 25/71 (35) 27/64 (42) 38/64 (59) KIT Pathway Alterations in…”
Jiveskog, S., Ragnarsson-Olding, B., Platz, A., & Ringborg, U. (1998) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1998.00376.x · Cited by 155
Self-citation
Cited by
Garbe, C., Peris, K., Hauschild, A., Saiag, P., Middleton, M., Bastholt, L., Grob, J.-J., Malvehy, J., Newton-Bishop, J., Stratigos, A. J., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.05.005 · Cited by 605
Metadata
- Authors
- Omholt, K., Grafström, E., Kanter-Lewensohn, L., Hansson, J., & Ragnarsson-Olding, B. K.
- Venue
- Clinical Cancer Research
- Published
- 2011-06-15
- Volume
- 17
- Issue
- 12
- Pages
- 3933-3942
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2098647445
- Cited by
- 194
- References
- 3
- FWCI
- 6.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: KIT Pathway Alterations in Mucosal Melanomas of the Vulva and Other Sites. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-10-2917
- The paper
- Omholt, K., Grafström, E., Kanter-Lewensohn, L., Hansson, J., & Ragnarsson-Olding, B. K. (2011). KIT Pathway Alterations in Mucosal Melanomas of the Vulva and Other Sites. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-10-2917
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.